FRANKFURT, May 6 (Reuters) - A spokesman for GlaxoSmithKline
on Wednesday declined to comment on a report by IFR,
saying the British drugmaker was selling a block of shares in
Hindustan Unilever worth $3.4 billion on the open
market.
In December 2018 GSK agreed to sell malted drink brand
Horlicks and other nutrition brands to Unilever for
$3.8 billion. At the time it accepted as partial payment a stake
in a planned joint venture between GSK's Indian business - whose
main product is Horlicks - and Unilever's Indian unit Hindustan
Unilever.
(Reporting by Ludwig Burger, editing by Louise Heavens)